Shaping the future of modern drug discovery

Pharmaceutical and biotechnological industries often depend on the information acquired through basic research. To develop new drugs, for instance, companies need to stay up to date about the latest discoveries in genomics, proteomics, structural or quantitative biology and learn how to translate this knowledge into a new product. In his interview with Switzerland Innovation Park innovaare, Professor Dr. Gebhardt Schertler, Head of the Division of Biology and Chemistry at the Paul Scherrer Institute (PSI), one of the brightest minds in structural biology, shares his views on the challenges and opportunities of modern drug discovery and the role of basic research. Watch the full video and find out more about drug discovery here:

Interview with Prof. Schertler